chugai

You are now moving to an external website.
Disclaimer
This link will lead you to leave the website of Chugai Pharma Taiwan; the content of the linked website you choose (links, changes, or updates in this website) is no longer the responsibility of Chugai Pharma Taiwan. Chugai Pharma Taiwan does not take any legal responsibility for the information transmitted by this linked website.This link is for your convenience only, and any link does not mean that Chugai Pharma Taiwan endorses or approves its website content.

Access the link

Autoimmune
Actemra Solution for Infusion
衛署菌疫輸字第000907號
Product Introduction
test

Actemra 80mg Solution for Infusion

Indications:

1.Rheumatoid Arthritis (RA):

ACTEMRA in combination with methotrexate (MTX) is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumor necrosis factor (TNF) antagonists. In these patients, ACTEMRA can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.ACTEMRA has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function when given in combination with methotrexate measured by HAQ-DI score.

test

Actemra 200mg Solution for Infusion

2.Rheumatoid Arthritis (RA) - MTX naïve RA:

ACTEMRA in combination with methotrexate (MTX) is indicated for the treatment of severe, active and progressive rheumatoid arthritis in adult patients not previously treated with MTX. In these patients, ACTEMRA can be given as monotherapy in case of intolerant to MTX or where continued treatment with MTX is inappropriate. ACTEMRA has been shown to reduce the rate of progression of joint damage as measured by X-ray when given in combination with methotrexate.

test

3.Polyarticular Juvenile Idiopathic Arthritis (PJIA):

ACTEMRA in combination with methotrexate (MTX) is indicated for the treatment of polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older, who have responded inadequately to previous therapy with MTX. Actemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.

test

4.Systemic Juvenile Idiopathic Arthritis (SJIA):

ACTEMRA is indicated for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 2 years of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids.

Product Specification
Product Name
Actemra 80mg Solution for Infusion

Actemra 200mg Solution for Infusion